LSLina Siukstaite

Lina Siukstaite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lina Siukstaite has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Engineered coiled-coils convert cholera toxin B-pentamers into programmable membrane fusogens

    by Wenyue Dai, Erik Kempmann, Francesca Rosato, Maria Nikolova, Lina Siukstaite, Tomasz P. Kamiński, Andrew Booth, Maryam S. K. Ishmael, Chunyue Wang, George R. Heath, et al.

    Membrane fusion underpins many fundamental cellular processes, yet the design of artificial fusogens that can interact with specific cell surface markers in a precise and predictable manner remains a major challenge. Here we demonstrate that cholera toxin B-subunit (CTB), a naturally occurring glycolipid-binding pentamer, can be re-engineered into a programmable membrane fusogen by assembling two CTB units through rationally designed coiled-coil linkers attached to the CTA2 peptide that threads through the CTB pentamer. Using discrete parallel and antiparallel coiled-coil architectures, we generated CTB dimers with defined orientations and examined their ability to drive fusions of giant unilamellar vesicles containing the CTB ligand ganglioside GM1. Fusion efficiency was evaluated using a fluorescence resonance energy transfer (FRET)-based lipid mixing assay, while flow cytometry, confocal microscopy and quartz crystal microbalance with dissipation monitoring (QCM-D) provided mechanistic insights. Both parallel and antiparallel CTB dimers induced cross-linking and full fusion of vesicles, with the efficiency of fusion governed primarily by the length of the CTA peptide linker rather than coiled-coil orientation. These findings establish a robust strategy to engineer lectin-based fusogens with tunable activity, providing new opportunities for the development of targeted membrane fusion systems for drug delivery and synthetic biology.

  • Open Access

    The Schizosaccharomyces pombe Glycosyltransferase Gmh5 is a Functional Homologue of the α-1,6-Mannosyltransferase Mnn10 Crucial for N-Glycan Processing

    by Mark Lommel, Franziska Hutzler, Lina Siukstaite, Klemens Wild, Antonija Grbavac, Irmgard Sinning, Sabine Strahl

    Research background. Glycosyltransferases represent a large and diverse family of enzymes that catalyze the transfer of sugar residues to proteins and lipids, thereby regulating essential cellular processes such as protein quality control and cell wall biosynthesis. In yeast, protein O-mannosyltransferases and other glycosyltransferases are crucial for maintaining cell wall integrity. While the functions of many of these enzymes are well characterized, the role of some of them, such as Gmh5p, remains unknown. This study aims to elucidate the function of Gmh5p, a previously uncharacterized member of the GT34 glycosyltransferase family, in the context of protein and cell wall biosynthesis in Schizosaccharomyces pombe. Experimental approach. To identify proteins and pathways compensating for reduced O-mannosylation, we performed a genetic screening for multi-copy suppressors in a conditional lethal nmt81-oma2+ mutant background. The enzymatic activity of Gmh5p was biochemically characterized, and its functional homology to known mannosyltransferases was assessed through complementation experiments in Saccharomyces cerevisiae. In addition, the N-glycosylation status of model substrates was analyzed in gmh5Δ mutant strains. Results and conclusions. Gmh5p was identified as a suppressor of O-mannosylation defects. Contrary to its predicted function, Gmh5p did not exhibit α-1,2-galactosyltransferase activity but instead showed mannosyltransferase activity. Expression of gmh5+ in S. cerevisiae mnn10 mutants restored hygromycin tolerance to near wild-type levels. Furthermore, N-glycosylation of model substrates was reduced in gmh5Δ mutants. These results demonstrate that Gmh5p is a mannosyltransferase involved in the outer chain elongation of N-linked glycans and functions as a homologue of Mnn10p. Novelty and scientific contribution. This study provides the first functional characterization of Gmh5p as a mannosyltransferase of the GT34 family and demonstrates its role in N-glycan biosynthesis. Our findings expand the current understanding of the diversity and specificity of glycosyltransferases in eukaryotes and highlight their importance in cell wall biology.

  • Open Access

    Enzymatic Glyco-Modification of Synthetic Membrane Systems

    by Dylan Jabeguero, Lina Siukstaite, Chunyue Wang, Anna Mitrovic, Serge Pérez, Olga Makshakova, Ralf P. Richter, Winfried Römer, Christelle Breton

    The present report assesses the capability of a soluble glycosyltransferase to modify glycolipids organized in two synthetic membrane systems that are attractive models to mimic cell membranes: giant unilamellar vesicles (GUVs) and supported lipid bilayers (SLBs). The objective was to synthesize the Gb3 antigen (Galα1,4Galβ1,4Glcβ-Cer), a cancer biomarker, at the surface of these membrane models. A soluble form of LgtC that adds a galactose residue from UDP-Gal to lactose-containing acceptors was selected. Although less efficient than with lactose, the ability of LgtC to utilize lactosyl–ceramide as an acceptor was demonstrated on GUVs and SLBs. The reaction was monitored using the B-subunit of Shiga toxin as Gb3-binding lectin. Quartz crystal microbalance with dissipation analysis showed that transient binding of LgtC at the membrane surface was sufficient for a productive conversion of LacCer to Gb3. Molecular dynamics simulations provided structural elements to help rationalize experimental data.


  • Open Access

    Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells

    by Ana Valeria Meléndez, Rubí M.-H. Velasco Cárdenas, Simon Lagies, Juliane Strietz, Lina Siukstaite, Oliver S. Thomas, Jana Tomisch, Wilfried Weber, Bernd Kammerer, Winfried Römer, et al.

    The link between cancer and aberrant glycosylation has recently become evident. Glycans and their altered forms, known as tumour-associated carbohydrate antigens (TACAs), are diverse, complex and difficult to target therapeutically. Lectins are naturally occurring glycan-binding proteins that offer a unique opportunity to recognise TACAs. T cells expressing chimeric antigen receptors (CARs) have proven to be a successful immunotherapy against leukaemias, but so far have shown limited success in solid tumours. We developed a panel of lectin-CARs that recognise the glycosphingolipid globotriaosylceramide (Gb3), which is overexpressed in various cancers, such as Burkitt's lymphoma, colorectal, breast and pancreatic. We have selected the following lectins: Shiga toxin's B-subunit from Shigella dysenteriae, LecA from Pseudomonas aeruginosa, and the engineered lectin Mitsuba from Mytilus galloprovincialis as antigen-binding domains and fused them to a well-known second-generation CAR. The Gb3-binding lectin-CARs have demonstrated target-specific cytotoxicity against Burkitt's lymphoma-derived cell lines as well as solid tumour cells from colorectal and triple-negative breast cancer. Our findings reveal the big potential of lectin-based CARs as therapeutical applications to target Gb3 and other TACAs expressed in haematological malignancies and solid tumours.


  • Open Access

    Extending Janus lectins architecture: characterization and application to protocells

    by Simona Notova, Lina Siukstaite, Francesca Rosato, Federica Vena, Aymeric Audfray, Nicolai Bovin, Ludovic Landemarre, Winfried Römer, Anne Imberty

    Synthetic biology is a rapidly growing field with applications in biotechnology and biomedicine. Through various approaches, remarkable achievements, such as cell and tissue engineering, have been already accomplished. In synthetic glycobiology, the engineering of glycan binding proteins is being developed for producing tools with precise topology and specificity. We developed the concept of chimeric lectins, i.e., Janus lectin, with increased valency, and additional specificity. The novel engineered lectin, assembled as a fusion protein between the β-propeller domain from Ralstonia solanacearum and the β-trefoil domain from fungus Marasmius oreades , is specific for fucose and α-galactose and its unique protein architecture allows to bind these ligands simultaneously. The protein activity was tested with glycosylated giant unilamellar vesicles, resulting in the formation of proto-tissue-like structures through cross-linking of such protocells. The synthetic protein binds to H1299 lung epithelial cancer cells by its two domains. The biophysical properties of this new construct were compared with the two already existing Janus lectins, RSL-CBM40 and RSL-CBM77Rf. Denaturation profiles of the proteins indicate that the fold of each has a significant role in protein stability and should be considered during protein engineering.


  • Open Access

    A pore-forming β-trefoil lectin with specificity for the tumor-related glycosphingolipid Gb3

    by Simona Notova, François Bonnardel, Francesca Rosato, Lina Siukstaite, Jessica Schwaiger, Nicolai Bovin, Annabelle Varrot, Winfried Römer, Frédérique Lisacek, Anne Imberty

    Lectins are efficient multivalent glycan receptors, deciphering the glyco-code on cell surfaces. The β-trefoil fold, characterized by three lobe-shaped repeats, is adopted by several classes of lectins, often associated with other domains having enzymatic or toxic activity. Based on the UniLectin3D database classification, the sequence signature of trefoil lobes was defined and used to predict 44714 lectins from 4497 species. Among them, SaroL-1 from the lower eukaryote Salpingoeca rosetta was predicted to contain both β-trefoil and aerolysin-like pore-forming domain. Recombinant SaroL-1 binds to galactose and derivatives, with a stronger affinity for cancer-related α-galactosylated epitopes such as glycosphingolipid Gb3 embedded in giant unilamellar vesicles or cell membranes. Crystal structures in complex with Gb3 trisaccharide and GalNAc show similarity with pore-forming toxins. Recognition of the αGal epitope on glycolipids was necessary for hemolysis of rabbit erythrocytes and toxicity on cancer cells through carbohydrate-dependent pore-formation.


  • Open Access

    The Two Sweet Sides of Janus Lectin Drive Crosslinking of Liposomes to Cancer Cells and Material Uptake

    by Lina Siukstaite, Francesca Rosato, Anna Mitrovic, Peter Fritz Müller, Katharina Kraus, Simona Notova, Anne Imberty, Winfried Römer

    A chimeric, bispecific Janus lectin has recently been engineered with different, rationally oriented recognition sites. It can bind simultaneously to sialylated and fucosylated glycoconjugates. Because of its multivalent architecture, this lectin reaches nanomolar avidities for sialic acid and fucose. The lectin was designed to detect hypersialylation—a dysregulation in physiological glycosylation patterns, which promotes the tumor growth and progression of several cancer types. In this study, the characteristic properties of this bispecific Janus lectin were investigated on human cells by flow cytometry and confocal microscopy in order to understand the fundamentals of its interactions. We evaluated its potential in targeted drug delivery, precisely leading to the cellular uptake of liposomal content in human epithelial cancer cells. We successfully demonstrated that Janus lectin mediates crosslinking of glyco-decorated giant unilamellar vesicles (GUVs) and H1299 lung epithelial cells. Strikingly, the Janus lectin induced the internalization of liposomal lipids and also of complete GUVs. Our findings serve as a solid proof of concept for lectin-mediated targeted drug delivery using glyco-decorated liposomes as possible drug carriers to cells of interest. The use of Janus lectin for tumor recognition certainly broadens the possibilities for engineering diverse tailor-made lectin constructs, specifically targeting extracellular structures of high significance in pathological conditions.


  • Open Access

    Structural Diversities of Lectins Binding to the Glycosphingolipid Gb3

    by Lina Siukstaite, Anne Imberty, Winfried Römer

    Glycolipids are present on the surfaces of all living cells and thereby represent targets for many protein receptors, such as lectins. Understanding the interactions between lectins and glycolipids is essential for investigating the functions of lectins and the dynamics of glycolipids in living membranes. This review focuses on lectins binding to the glycosphingolipid globotriaosylceramide (Gb3), an attractive host cell receptor, particularly for pathogens and pathogenic products. Shiga toxin (Stx), from Shigella dysenteriae or Escherichia coli, which is one of the most virulent bacterial toxins, binds and clusters Gb3, leading to local negative membrane curvature and the formation of tubular plasma membrane invaginations as the initial step for clathrin-independent endocytosis. After internalization, it is embracing the retrograde transport pathway. In comparison, the homotetrameric lectin LecA from Pseudomonas aeruginosa can also bind to Gb3, triggering the so-called lipid zipper mechanism, which results in membrane engulfment of the bacterium as an important step for its cellular uptake. Notably, both lectins bind to Gb3 but induce distinct plasma membrane domains and exploit mainly different transport pathways. Not only, several other Gb3-binding lectins have been described from bacterial origins, such as the adhesins SadP (from Streptococcus suis) and PapG (from E. coli), but also from animal, fungal, or plant origins. The variety of amino acid sequences and folds demonstrates the structural versatilities of Gb3-binding lectins and asks the question of the evolution of specificity and carbohydrate recognition in different kingdoms of life.


  • Open Access

    PS12: Janus lectin mediated liposomal fusion to cancer cells

    by Lina Siukstaite

    Not only is it crucial to develop more efficient and new anticancer drugs, but it is also essential to develop ways to precisely deliver drugs to cancer cells and understand this process's fundamentals. The aberrant overexpression of specific glycosphingolipids tightly associates with the initiation of a tumor and its malignant transformation. Therefore, the carbohydrate-binding